Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

4 months ago
CGT,Clinical Development,News

Latest Advancements in Parkinson’s Treatment: CGT Shows Potential to Reverse Disease

Every hour, two more people are diagnosed with Parkinson’s in the UK and the global patient population continues to rise. To date, there are no disease-modifying therapies available on the market for Parkinson's (PD) patients. Pharmaceutical company Bayer is simultaneously...

4 months ago

A Review of CGT: Viral and Non-Viral Approaches

Cell and gene therapies have remained at the forefront of biomedical research for the last decade. While the mechanisms of these therapies differ, both approaches have shown potential across a range of conditions to alleviate symptoms or potentially cure the...

5 months ago
R&D,Bioprocess,CGT,Biology,News

A Review of CGT: Viral and Non-Viral Approaches

Cell and gene therapies have remained at the forefront of biomedical research for the last decade. While the mechanisms of these therapies differ, both approaches have shown potential across a range of conditions to alleviate symptoms or potentially cure the...

5 months ago

Future Trends for Pharma and Life Sciences 2021

Given the considerable seismic shifts occurring in the pharmaceutical and life sciences sectors recently, it is no surprise that the major trends and investments of 2021 have seen a similar change in focus. Alzheimer’s Disease, genome editing and cellular therapy...

5 months ago
Oncology,R&D,CGT,Precision and Personalised Medicine,Biology,News

Future Trends for Pharma and Life Sciences 2021

Given the considerable seismic shifts occurring in the pharmaceutical and life sciences sectors recently, it is no surprise that the major trends and investments of 2021 have seen a similar change in focus. Alzheimer’s Disease, genome editing and cellular therapy...

5 months ago

Solving Regulatory Issues in Cell and Gene Therapies

Cell and Gene Therapies (CGTs), experimental technologies to treat or cure diseases using the body’s cells, have been on the ascendant for some time now. As promising as they are, CGTs have consistently moved forward faster than regulatory agencies can...

1 year ago
Bioprocess,CGT,Biomanufacturing,Regulatory Affairs,News

Solving Regulatory Issues in Cell and Gene Therapies

Cell and Gene Therapies (CGTs), experimental technologies to treat or cure diseases using the body’s cells, have been on the ascendant for some time now. As promising as they are, CGTs have consistently moved forward faster than regulatory agencies can...

1 year ago

How will COVID-19 Change Biomanufacturing?

The COVID-19 pandemic proved how ill-equipped the world was for a virus of that scale and potency. In the first months of the pandemic, businesses across all sectors scrambled to prepare their processes and supply chains for the coming disruption,...

1 year ago
Bioprocess,CGT,Biomanufacturing,Regulatory Affairs,News

How will COVID-19 Change Biomanufacturing?

The COVID-19 pandemic proved how ill-equipped the world was for a virus of that scale and potency. In the first months of the pandemic, businesses across all sectors scrambled to prepare their processes and supply chains for the coming disruption,...

1 year ago

The Challenges of CMC in Cell and Gene Therapies

Safety is one of the most important aspects of drug development. The need for a drug to be efficacious, consistent and non-harmful to humans is vital for its success. And where a treatment is new, highly variable, and can involve...

1 year ago
Bioprocess,CGT,Biomanufacturing,CMC,Regulatory Affairs,News

The Challenges of CMC in Cell and Gene Therapies

Safety is one of the most important aspects of drug development. The need for a drug to be efficacious, consistent and non-harmful to humans is vital for its success. And where a treatment is new, highly variable, and can involve...

1 year ago

Time to invest in CGT: Its Benefits for Pharma

The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...

2 years ago
Bioprocess,CGT,News

Time to invest in CGT: Its Benefits for Pharma

The concept of cell and gene therapy (CGT), wherein scientists and healthcare experts adapt cells and genes to treat illnesses, is nothing new in the life science space. Even the relatively new CRISPR has transformed into a household buzzword over...

2 years ago